Main Article Content
Aim and Objectives: This study aimed to evaluate the plasma levels of Growth Differentiation Factor-15 (GDF-15) in children with congestive heart failure, also to evaluate the diagnostic and prognostic value of this novel biomarker in pediatric congestive heart failure, by correlation of its levels with the clinical status and the echocardiographic data of these patients.
Subjects and Methods: This study was conducted on Thirty (30) children with congestive heart failure (CHF), Patients were selected from those admitted to Pediatric Cardiology Unit, Pediatric Department, Tanta University Hospital, from (August 2018-April 2020), and thirty (30) healthy children, matched for age and sex, were enrolled as a control group. All children in this study were subjected to Plain X-ray chest and heart: Cardiothoracic ratio (CTR) was measured, and Echocardiographic assessment: Doppler and Two-dimensional, M-mode Echocardiographic evaluation of these parameters and Plasma level of Growth Differentiation Factor-15 (GDF-15) was measured.
Results: the results revealed that The best cutoff point of GDF-15 to differentiate between cases with CHF and control group was >446.5 ng/l with 93.33% sensitivity, 90% specificity, 90.3% PPV, 93.1% NPV and AUC was 0.992.
There was significant decrease of EF% and FS% (systolic dysfunction of LV) in patients with CHF as compared to control group.
There was statistically significant positive correlation between plasma level of GDF-15 and Ross clinical stage of CHF.
There was statistically significant negative correlation between GDF-15 and EF%, FS % by echocardiography.
Conclusion: Plasma levels of GDF-15 were elevated in children with CHF, and these levels were correlated to the Ross staging of CHF and echocardiographic assessment of LV function. Plasma levels of GDF-15 were elevated in patients with bad prognosis, denoting its prognostic value as a novel biomarker in pediatric CHF.
Clark BJ. Treatment of heart failure in infants and children. Heart disease (Hagerstown, Md.) 2.5. 2000;354.
Johnson FL. Pathophysiology and etiology of heart failure. Cardiol Clin. 2014; 32(1):9-19.
Jayaprasad N. Heart failure in children. Heart Views: The Official Journal of the Gulf Heart Association. 2016;17(3): 92.
Kay JD, Colan SD, Graham TP. Congestive heart failure in pediatric patients. American Heart Journal. 2001; 142(5):923-928.
Foris V, Kovacs G, Tscherner M. Biomarkers in pulmonary hypertension: what do we know? Chest. 2013;144(1): 274-283.
Li G, Li Y, Tan X Q. Plasma growth differentiation factor-15 is a potential biomarker for pediatric pulmonary arterial hypertension associated with congenital heart disease. Pediatric Cardiology. 2017; 38(8):1620-1626.
Adela R, Banerjee S K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: A translational prospective. Journal of Diabetes Research. 2015;70:219-228.
Bauskin AR, Zhang HP, Fairlie WD. The propeptide of macrophage inhibitory cytokine (MIC‐1), a TGF‐β superfamily member, acts as a quality control determinant for correctly folded MIC‐1. The EMBO Journal .2000;19(10):2212-2220.
Breit, Samuel N. The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors. 2011; 29(5):187-95.
Zimmers TA, Jin X, Hsiao EC. Growth differentiation factor-15: Induction in liver injury through p53 and tumor necrosis factor-independent mechanisms1. Journal of Surgical Research. 2006;130(1):45-51.
Gaggin HK, Szymonifka J, Bhardwaj. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC: Heart Failure. 2014;2(1):65-72.
Wang F, Guo Y, Yu H. Growth differentiation factor 15 in different stages of heart failure: Potential screening implications. Biomarkers. 2010;15(8):671-676.
Lok DJ, Klip IT, Lok SI. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. The American Journal of Cardiology. 2013;112(6):831-837.
Azevedo, Vitor MP. The impact of malnutrition on idiopathic dilated cardiomyopathy in children (in Portuguese). Jpediatr (RioJ). 2004;80:211-6.
Von Haehling S, doehner W, Anker SD. Nutrition, metabolism, and complex pathophysiology of cachexia in chronic heart failure. Cardiovascular research. 2007;73(2):298-309.
Mocumbi AO, Lameira E, Yaksh A. Challenges on the management of congenital heart disease in developing countries. International Journal of Cardiology. 2011;148(3):285-288.
Erickson LC. Medical issues for the cardiac patient. In: Critical Care of Infants and Children. 2007;259-62.
Abou-Raya S, Naim A, Marzouk S. Cardiac matrix remodelling in congestive heart failure: The role of matrix metalloproteinases. Clinical and Investigative Medicine. 2004;27(2):93.
Banerjee Prithwish, Khand. Diastolic heart failure: Neglected or misdiagnosed? Journal of the American College of Cardiology. 2002;39(1):138-141.
Li Y, Wang XM, Liu YL. Plasma concentration of growth-differentiation factor-15 in children with congenital heart disease: Relationship to heart function and diagnostic value in heart failure. Zhongguo Dang dai er ke za zhi= Chinese Journal of Contemporary Pediatrics. 2013;15(2):95-98.
Nair N, Enrique G. Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology?. Journal of Circulating Biomarkers 7. 2018: 1849454417751735.
Kempf T, Horn-Wichmann R, Brabant G. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clinical Chemistry. 2007;53(2):284-291.